Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

UNLIMITED

STAT

STAT+: Pharmalittle: We’re reading about Editas layoffs, House Republicans probing CVS, and more

Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda includes tidying up around the castle, catching up on our reading, promenading with the official mascots,, , , and . And what about you? As some holidays approach, you may find this is an appropriate time to rummage through catalogs or visit your local temple of consumption for a shopping excursion. Conversely, you could remain indoors and binge-watch whatever is on the telly. You could plan a getaway or — if you feel ambitious — map out the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: With Promising Early Data In Triple Negative Breast Cancer, A New Bispecific Heats Up
New data suggests researchers may have found one of their most promising candidates yet for the next generation in immunotherapy drugs — bispecific antibodies targeting two key proteins in cancer, PD1 or PD-L1 and VEGF.A small early trial on one such
STAT1 min read
Opinion: The Surgeon General Is Right: America Has A Drinking Problem
The alcohol industry relies on the myth of “responsible enjoyment” to downplay its products’ risks while spreading misinformation to stifle regulation.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Novo And GLP-1 Compounding, Paxlovid And Long Covid, And More
Novo Nordisk filed another petition with the FDA seeking to block compounding pharmacies from making versions of one of its GLP-1 drugs

Related Books & Audiobooks